Introduction
India is the 2nd most populous country in the world with a population of approximately 1.2 billion. Only a small minority of the population of the country is insured or has the economic capability to afford standard-of-care medical care especially highend, expensive biotherapeutic products. Mass affordability is a genuine problem in India and other developing countries. Because of this pressure, the regulatory process reflects a complex interplay between economics, science, public health and politics.
In terms of volume, India is the world's 2nd largest supplier of vaccines and 4th largest supplier of pharmaceuticals. The country also has a robust biopharma sector with over 100 companies actively engaged in development or production of copy biotherapeutic products. The emphasis of the Indian biopharma industry had been directed more toward development of 'copies' rather than original molecules because of much lower developmental costs and risks, reduced spending on research and development, reduced time to market and expertise in reverse engineering drug development process. Over 50 different brands of copy products are approved for more than 20 different biopharmaceutical companies and some of these molecules have completed a decade of market presence with several thousand doses already administered. Even though there have been some concerns and questions that all locally manufactured products are not truly biosimilars, their acceptance by, both, the prescribers and the patients has been good [3, 4] .
Strict guidelines have been laid down by the Indian Regulatory bodies for the approval of Indian non-innovator/copy products. These have been published and are available on the website of the Central Drug Standard Control Organization and the Schedule Y of the Drug and Cosmetic Rules. These are based on the recommendations of a Task force on recombinant-pharmaceuticals accepted by the government of India in January 2006 [5] .
The Indian guidelines for the approval process of noninnovator/copy products [6] are to some extent different from the EMA and the recently published WHO guidelines. In the present review, an attempt will be made to provide the present status of the non-innovator biotherapeutic industry in India and the regulatory processes governing the approval of the same. The difference between the WHO and the Indian guidelines will be highlighted.
Non-innovator biotherapeutic industry in India
The opportunity for marketing non-innovator products in India is huge e approximately 50 biologicals patented prior to 1995 are now marketable in the country. To exploit this demand several home-grown biopharma industries are now actively developing and marketing non-innovator products in India.
The intensity of competition can be gauged from Table 1 . Presently, there are 16 brands of Erythropoietin (EPO) and 14 brands of granulocyte colony stimulating factor (G-CSF) available in the Indian market and new ones are being added every few months [4] . There have been concerns regarding the quality of available molecules and questions whether these copy products are at all 'similar' to the innovator products. Another major concern in India and other developing countries has been the maintenance of the cold chain at the stockist level and the viability of the product when it reaches the consumer.
Global market for Indian non-innovator products was anticipated to be approximately USD 1.5 billion in 2006 with a compounded annual growth rate of 27%. It is estimated that the exports of Indian biopharma products are increasing at the rate of 47% (2008) [4] .
Availability of non-innovator products provides major price advantages to the patients as innovators sometimes drop prices by 30e50%, sometimes 2e3 years ahead of launch of the biosimilar product. As a generalization, prices of non-innovator products are approximately 45e75% of the price of the innovator product [4] .
In India, there has been good acceptance of non-innovator products amongst health care professionals and patients. For example of the total sales of G-GCF, 65% is comprised of noninnovator products by volume and for EPO, these non-innovator products account for 40% of total annual sales [4] .
The Indian regulators are attempting to ensure a high quality of the products. The recently published and released (August 2010) 6th Edition of the Indian Pharmacopoeia includes product-specific monographs for 5 biological drug substances including insulin, interferon, EPO, G-CSF and streptokinase and monographs for other biologic products are under development [7] .
Indian regulatory process for non-innovator biotherapeutic products
The Indian regulatory system for non-innovator products is a stand-alone system and is followed for all the biotechnologyderived products since 1996 [5, 6] . There are several departments and committtees involved ( Table 2 ). The regulations for noninnovator products are different from the published WHO and the EMA guidelines ( Table 3 ). The approval requirements for any new non-innovator product are shown in Fig. 1 . These comprise physico-chemical and biological characterization, non-clinical toxicity studies and Phase III confirmatory clinical trials. None of the assessment includes any comparative testing at all.
The regulatory process has defined protocols for 5 scenarios for which committee clearances are mandatory. For example, products without Live Micro-organisms (LMO) could be: 
Dossier requirements
The Indian regulatory authorities have specified the dossier requirements for submission for approvals of non-innovator biotherapeutic products [6] . The dossier needs to have considerable information; relevant details are provided in Table 4 and below:
Non-clinical studies
These need to assess single dose toxicity (dose tolerance), repeat dose toxicity (also with recovery period), local tolerance and allergenicity and have to be done in at least two relevant species with route of administration resembling clinics (IV/IM/SC) and with control animals in each study (vehicle control) [6] .
These studies can be non-comparative and comparative study is not a regulatory requirement but some large companies are performing comparisons. 
Summary & conclusions
With more and more innovator/RBP going off patent, urgent attention is required to regulate the increasing number of copy biotherapeutics. New non-innovator biotherapeutics should be made available as soon as patent protection is over so that the economically compromised patients who cannot afford the high cost of the originator molecule have an option to opt for the cheaper copy versions. Reducing the cost of drugs is now a global priority rather than just being a major issue in developing economies [8] . Biopharma industry in many developing countries is ready and capable of manufacturing world-class non-innovator biotherapeutic products. However, it is imperative that the local regulatory authorities ensure that the manufacturer maintains the quality and consistency of the finished product across batches over time [9] . This can be a major challenge especially in developing countries [10, 11] .
The costs associated with conducting comparative clinical trials should not be so high that the new manufacturer is unable to perform the trial or passes on the cost of the trial to the patient making the non-innovator product out of economic reach for the majority of patients. Efficacy and safety of non-innovator products should be ensured by the national regulatory authorities.
Developing specific guidelines is important for approval of copy biotherapeutics in India. Like guidelines for vaccines, productspecific guidelines for biosimilar products are needed. These should include various aspects e.g. quality of the product, pharmaco vigilance, cold chain maintenance etc.
